Severe haemophilia A with haemarthrosis improved on emicizumab: A case report
Severe haemophilia A is associated with serious spontaneous bleeding in muscles, soft tissues, and joints. Haemarthrosis, bleeding into joints, is a serious complication of haemophilia. Emicizumab is a novel non-factor replacement agent for preventing or reducing the frequency of bleeding episodes i...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2025-03-01
|
| Series: | The Journal of Haemophilia Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/jhp-2025-0004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839612584750219264 |
|---|---|
| author | Wasifuddin Mustafa Al-Gaithi Ibrahim |
| author_facet | Wasifuddin Mustafa Al-Gaithi Ibrahim |
| author_sort | Wasifuddin Mustafa |
| collection | DOAJ |
| description | Severe haemophilia A is associated with serious spontaneous bleeding in muscles, soft tissues, and joints. Haemarthrosis, bleeding into joints, is a serious complication of haemophilia. Emicizumab is a novel non-factor replacement agent for preventing or reducing the frequency of bleeding episodes in adults and children with haemophilia A with or without inhibitors. |
| format | Article |
| id | doaj-art-2a54aa1b06f948d7bd25db1df1eb981c |
| institution | Matheson Library |
| issn | 2055-3390 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Sciendo |
| record_format | Article |
| series | The Journal of Haemophilia Practice |
| spelling | doaj-art-2a54aa1b06f948d7bd25db1df1eb981c2025-07-28T06:09:38ZengSciendoThe Journal of Haemophilia Practice2055-33902025-03-01121293310.2478/jhp-2025-0004Severe haemophilia A with haemarthrosis improved on emicizumab: A case reportWasifuddin Mustafa0Al-Gaithi Ibrahim1Department of Medicine, Brookdale University Hospital and Medical Center, Brooklyn, New York, USADepartment of Pediatric Hematology/Oncology, Royal Hospital, Ministry of Health,Muscat, Oman.Severe haemophilia A is associated with serious spontaneous bleeding in muscles, soft tissues, and joints. Haemarthrosis, bleeding into joints, is a serious complication of haemophilia. Emicizumab is a novel non-factor replacement agent for preventing or reducing the frequency of bleeding episodes in adults and children with haemophilia A with or without inhibitors.https://doi.org/10.2478/jhp-2025-0004emicizumabhaemophilia ableedingquality of lifecase report |
| spellingShingle | Wasifuddin Mustafa Al-Gaithi Ibrahim Severe haemophilia A with haemarthrosis improved on emicizumab: A case report The Journal of Haemophilia Practice emicizumab haemophilia a bleeding quality of life case report |
| title | Severe haemophilia A with haemarthrosis improved on emicizumab: A case report |
| title_full | Severe haemophilia A with haemarthrosis improved on emicizumab: A case report |
| title_fullStr | Severe haemophilia A with haemarthrosis improved on emicizumab: A case report |
| title_full_unstemmed | Severe haemophilia A with haemarthrosis improved on emicizumab: A case report |
| title_short | Severe haemophilia A with haemarthrosis improved on emicizumab: A case report |
| title_sort | severe haemophilia a with haemarthrosis improved on emicizumab a case report |
| topic | emicizumab haemophilia a bleeding quality of life case report |
| url | https://doi.org/10.2478/jhp-2025-0004 |
| work_keys_str_mv | AT wasifuddinmustafa severehaemophiliaawithhaemarthrosisimprovedonemicizumabacasereport AT algaithiibrahim severehaemophiliaawithhaemarthrosisimprovedonemicizumabacasereport |